Avi Smith
Research Subjects
Avi Smith has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan A. Garlick
Program in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America
10 shared publications - David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
6 shared publications Jonathan A. Garlick
Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, USA
6 shared publicationsAnna G. Maione
Department of Diagnostic Sciences, School of Dental Medicine, Tufts University, Boston, Massachusetts, USA
5 shared publicationsAristidis Veves
Microcirculation Laboratory, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
3 shared publicationsBehzad Gerami-Naini
Tufts University
3 shared publications
Latest Publications
- 31 May 2024
- Published by Springer Nature
- p. 253-271
Cell Therapies: New Frontier for the Management of Diabetic Foot Ulceration
- 31 May 2024
- Published by Springer Nature
- p. 253-271
Cell Therapies: New Frontier for the Management of Diabetic Foot Ulceration
- 1 February 2021
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 27 (2) , 49-58
A Novel Three-Dimensional Skin Disease Model to Assess Macrophage Function in Diabetes
A major challenge in the management of patients suffering from diabetes is the risk of developing nonhealing foot ulcers. Most in vitro methods to screen drugs for wound healing therapies rely on conventional 2D cell cultures that do not closely mimic the complexity of the diabetic wound environment. In addition, while three-dimensional (3D) skin tissue models of human skin exist, they have not previously been adapted to incorporate patient-derived macrophages to model inflammation from these wounds. In this study, we present a 3D human skin equivalent (HSE) model incorporating blood-derived monocytes and primary fibroblasts isolated from patients with diabetic foot ulcers (DFUs). We demonstrate that the monocytes differentiate into macrophages when incorporated into HSEs and secrete a cytokine profile indicative of the proinflammatory M1 phenotype seen in DFUs. We also show how the interaction between fibroblasts and macrophages in the HSE can guide macrophage polarization. Our findings take us a step closer to creating a human, 3D skin-like tissue model that can be applied to evaluate the response of candidate compounds needed for potential new foot ulcer therapies in a more complex tissue environment that contributes to diabetic wounds. Impact statement: This study is the first to incorporate disease-specific, diabetic macrophages into a three-dimensional (3D) model of human skin. We show how to fabricate skin that incorporates macrophages with disease-specific fibroblasts to guide macrophage polarization. We also show that monocytes from diabetic patients can differentiate into macrophages directly in this skin disease model, and that they secrete a cytokine profile mimicking the proinflammatory M1 phenotype seen in diabetic foot ulcers. The data presented here indicate that this 3D skin disease model can be used to study macrophage-related inflammation in diabetes and as a drug testing tool to evaluate new treatments for the disease.
- 1 February 2021
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 27 (2) , 49-58
A Novel Three-Dimensional Skin Disease Model to Assess Macrophage Function in Diabetes
A major challenge in the management of patients suffering from diabetes is the risk of developing nonhealing foot ulcers. Most in vitro methods to screen drugs for wound healing therapies rely on conventional 2D cell cultures that do not closely mimic the complexity of the diabetic wound environment. In addition, while three-dimensional (3D) skin tissue models of human skin exist, they have not previously been adapted to incorporate patient-derived macrophages to model inflammation from these wounds. In this study, we present a 3D human skin equivalent (HSE) model incorporating blood-derived monocytes and primary fibroblasts isolated from patients with diabetic foot ulcers (DFUs). We demonstrate that the monocytes differentiate into macrophages when incorporated into HSEs and secrete a cytokine profile indicative of the proinflammatory M1 phenotype seen in DFUs. We also show how the interaction between fibroblasts and macrophages in the HSE can guide macrophage polarization. Our findings take us a step closer to creating a human, 3D skin-like tissue model that can be applied to evaluate the response of candidate compounds needed for potential new foot ulcer therapies in a more complex tissue environment that contributes to diabetic wounds. Impact statement: This study is the first to incorporate disease-specific, diabetic macrophages into a three-dimensional (3D) model of human skin. We show how to fabricate skin that incorporates macrophages with disease-specific fibroblasts to guide macrophage polarization. We also show that monocytes from diabetic patients can differentiate into macrophages directly in this skin disease model, and that they secrete a cytokine profile mimicking the proinflammatory M1 phenotype seen in diabetic foot ulcers. The data presented here indicate that this 3D skin disease model can be used to study macrophage-related inflammation in diabetes and as a drug testing tool to evaluate new treatments for the disease.
- 1 February 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 114, 104174
The lubricating effect of iPS-reprogrammed fibroblasts on collagen-GAG scaffolds for cartilage repair applications
- 1 February 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 114, 104174
The lubricating effect of iPS-reprogrammed fibroblasts on collagen-GAG scaffolds for cartilage repair applications
- 1 June 2020
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 14 (8) , 1019-1027
De novo production of human extracellular matrix supports increased throughput and cellular complexity in 3D skin equivalent model
Three‐dimensional (3D) tissue models of human skin are being developed to better understand disease phenotypes and to screen new drugs for potential therapies. Several factors will increase the value of these in vitro 3D skin tissues for these purposes. These include the need for human‐derived extracellular matrix (ECM), higher throughput tissue formats and greater cellular complexity. Here we present an approach for the fabrication of 3D skin‐like tissues as a platform that addresses these three considerations. We demonstrate that human adult and neonatal fibroblasts deposit an endogenous ECM de novo that serves as an effective stroma for full epithelial tissue development and differentiation. We have miniaturized these tissues to a 24‐well format to adapt them for eventual higher throughput drug screening. We have shown that monocytes from the peripheral blood can be incorporated into this model as macrophages to increase tissue complexity. This humanized skin‐like tissue decreases dependency on animal‐derived ECM while increasing cellular complexity that can enable screening inflammatory responses in tissue models of human skin.
- 1 June 2020
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 14 (8) , 1019-1027
De novo production of human extracellular matrix supports increased throughput and cellular complexity in 3D skin equivalent model
Three‐dimensional (3D) tissue models of human skin are being developed to better understand disease phenotypes and to screen new drugs for potential therapies. Several factors will increase the value of these in vitro 3D skin tissues for these purposes. These include the need for human‐derived extracellular matrix (ECM), higher throughput tissue formats and greater cellular complexity. Here we present an approach for the fabrication of 3D skin‐like tissues as a platform that addresses these three considerations. We demonstrate that human adult and neonatal fibroblasts deposit an endogenous ECM de novo that serves as an effective stroma for full epithelial tissue development and differentiation. We have miniaturized these tissues to a 24‐well format to adapt them for eventual higher throughput drug screening. We have shown that monocytes from the peripheral blood can be incorporated into this model as macrophages to increase tissue complexity. This humanized skin‐like tissue decreases dependency on animal‐derived ECM while increasing cellular complexity that can enable screening inflammatory responses in tissue models of human skin.
- 1 March 2020
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 102, 106663
Utilization of a mouse/human chimeric model for long term metabolic testing of human skin
- 1 March 2020
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 102, 106663
Utilization of a mouse/human chimeric model for long term metabolic testing of human skin
- 9 November 2019
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (5) , 791-801
Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase–like 4: New Evidence From Three‐Dimensional Skin‐like Tissues
Objective: Systemic sclerosis (SSc) is a clinically heterogeneous disease characterized by increased collagen accumulation and skin stiffness. Our previous work has demonstrated that transforming growth factor β (TGFβ) induces extracellular matrix (ECM) modifications through lysyl oxidase–like 4 (LOXL‐4), a collagen crosslinking enzyme, in bioengineered human skin equivalents (HSEs) and self‐assembled stromal tissues (SAS). We undertook this study to investigate cutaneous fibrosis and the role of LOXL‐4 in SSc pathogenesis using HSEs and SAS.Methods: SSc‐derived dermal fibroblasts (SScDFs; n = 8) and normal dermal fibroblasts (NDFs; n = 6) were incorporated into HSEs and SAS. These 3‐dimensional skin‐like microenvironments were used to study the effects of dysregulated LOXL‐4 on ECM remodeling, fibroblast activation, and response to TGFβ stimulation.Results: SScDF‐containing SAS showed increased stromal thickness, collagen deposition, and interleukin‐6 secretion compared to NDF‐containing SAS (P < 0.05). In HSE, SScDFs altered collagen as seen by a more mature and aligned fibrillar structure (P < 0.05). With SScDFs, enhanced stromal rigidity with increased collagen crosslinking (P < 0.05), up‐regulation of LOXL4 expression (P < 0.01), and innate immune signaling genes were observed in both tissue models. Conversely, knockdown of LOXL4 suppressed rigidity, contraction, and α‐smooth muscle actin expression in SScDFs in HSE, and TGFβ‐induced ECM aggregation and collagen crosslinking in SAS.Conclusion: A limitation to the development of effective therapeutics in SSc is the lack of in vitro human model systems that replicate human skin. Our findings demonstrate that SAS and HSE can serve as complementary in vitro skin‐like models for investigation of the mechanisms and mediators that drive fibrosis in SSc and implicate a pivotal role for LOXL‐4 in SSc pathogenesis.
- 9 November 2019
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (5) , 791-801
Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase–like 4: New Evidence From Three‐Dimensional Skin‐like Tissues
Objective: Systemic sclerosis (SSc) is a clinically heterogeneous disease characterized by increased collagen accumulation and skin stiffness. Our previous work has demonstrated that transforming growth factor β (TGFβ) induces extracellular matrix (ECM) modifications through lysyl oxidase–like 4 (LOXL‐4), a collagen crosslinking enzyme, in bioengineered human skin equivalents (HSEs) and self‐assembled stromal tissues (SAS). We undertook this study to investigate cutaneous fibrosis and the role of LOXL‐4 in SSc pathogenesis using HSEs and SAS.Methods: SSc‐derived dermal fibroblasts (SScDFs; n = 8) and normal dermal fibroblasts (NDFs; n = 6) were incorporated into HSEs and SAS. These 3‐dimensional skin‐like microenvironments were used to study the effects of dysregulated LOXL‐4 on ECM remodeling, fibroblast activation, and response to TGFβ stimulation.Results: SScDF‐containing SAS showed increased stromal thickness, collagen deposition, and interleukin‐6 secretion compared to NDF‐containing SAS (P < 0.05). In HSE, SScDFs altered collagen as seen by a more mature and aligned fibrillar structure (P < 0.05). With SScDFs, enhanced stromal rigidity with increased collagen crosslinking (P < 0.05), up‐regulation of LOXL4 expression (P < 0.01), and innate immune signaling genes were observed in both tissue models. Conversely, knockdown of LOXL4 suppressed rigidity, contraction, and α‐smooth muscle actin expression in SScDFs in HSE, and TGFβ‐induced ECM aggregation and collagen crosslinking in SAS.Conclusion: A limitation to the development of effective therapeutics in SSc is the lack of in vitro human model systems that replicate human skin. Our findings demonstrate that SAS and HSE can serve as complementary in vitro skin‐like models for investigation of the mechanisms and mediators that drive fibrosis in SSc and implicate a pivotal role for LOXL‐4 in SSc pathogenesis.
- 1 April 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 99 (4) , 514-527
Lysyl oxidase enzymes mediate TGF-β1-induced fibrotic phenotypes in human skin-like tissues
- 1 April 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 99 (4) , 514-527
Lysyl oxidase enzymes mediate TGF-β1-induced fibrotic phenotypes in human skin-like tissues
- 1 September 2018
- Published by Elsevier in Molecular Cell
- Vol. 71 (5) , 825-840.e6
An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication
- 1 September 2018
- Published by Elsevier in Molecular Cell
- Vol. 71 (5) , 825-840.e6
An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication
- Open Access
- 8 August 2018
- Published by Wiley in The FASEB Journal
- Vol. 33 (1) , 1262-1277
Differentiation of diabetic foot ulcer–derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes
Diabetic foot ulcers (DFUs) are a major complication of diabetes, and there is a critical need to develop novel cell‐ and tissue‐based therapies to treat these chronic wounds. Induced pluripotent stem cells (iPSCs) offer a replenishing source of allogeneic and autologous cell types that may be beneficial to improve DFU wound‐healing outcomes. However, the biologic potential of iPSC‐derived cells to treat DFUs has not, to our knowledge, been investigated. Toward that goal, we have performed detailed characterization of iPSC‐derived fibroblasts from both diabetic and nondiabetic patients. Significantly, gene array and functional analyses reveal that iPSC‐derived fibroblasts from both patients with and those without diabetes are more similar to each other than were the primary cells from which they were derived. iPSC‐derived fibroblasts showed improved migratory properties in 2‐dimensional culture. iPSC‐derived fibroblasts from DFUs displayed a unique biochemical composition and morphology when grown as 3‐dimensional (3D), self‐assembled extracellular matrix tissues, which were distinct from tissues fabricated using the parental DFU fibroblasts from which they were reprogrammed. In vivo transplantation of 3D tissues with iPSC‐derived fibroblasts showed they persisted in the wound and facilitated diabetic wound closure compared with primary DFU fibroblasts. Taken together, our findings support the potential application of these iPSC‐derived fibroblasts and 3D tissues to improve wound healing.—Kashpur, O., Smith, A., Gerami‐Naini, B., Maione, A. G., Calabrese, R., Tellechea, A., Theocharidis, G., Liang, L., Pastar, I., Tomic‐Canic, M., Mooney, D., Veves, A., Garlick, J. A. Differentiation of diabetic foot ulcer–derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes. FASEB J. 33, 1262–1277 (2019). www.fasebj.org
- 8 August 2018
- Published by Wiley in The FASEB Journal
- Vol. 33 (1) , 1262-1277
Open AccessDifferentiation of diabetic foot ulcer–derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes
Diabetic foot ulcers (DFUs) are a major complication of diabetes, and there is a critical need to develop novel cell‐ and tissue‐based therapies to treat these chronic wounds. Induced pluripotent stem cells (iPSCs) offer a replenishing source of allogeneic and autologous cell types that may be beneficial to improve DFU wound‐healing outcomes. However, the biologic potential of iPSC‐derived cells to treat DFUs has not, to our knowledge, been investigated. Toward that goal, we have performed detailed characterization of iPSC‐derived fibroblasts from both diabetic and nondiabetic patients. Significantly, gene array and functional analyses reveal that iPSC‐derived fibroblasts from both patients with and those without diabetes are more similar to each other than were the primary cells from which they were derived. iPSC‐derived fibroblasts showed improved migratory properties in 2‐dimensional culture. iPSC‐derived fibroblasts from DFUs displayed a unique biochemical composition and morphology when grown as 3‐dimensional (3D), self‐assembled extracellular matrix tissues, which were distinct from tissues fabricated using the parental DFU fibroblasts from which they were reprogrammed. In vivo transplantation of 3D tissues with iPSC‐derived fibroblasts showed they persisted in the wound and facilitated diabetic wound closure compared with primary DFU fibroblasts. Taken together, our findings support the potential application of these iPSC‐derived fibroblasts and 3D tissues to improve wound healing.—Kashpur, O., Smith, A., Gerami‐Naini, B., Maione, A. G., Calabrese, R., Tellechea, A., Theocharidis, G., Liang, L., Pastar, I., Tomic‐Canic, M., Mooney, D., Veves, A., Garlick, J. A. Differentiation of diabetic foot ulcer–derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes. FASEB J. 33, 1262–1277 (2019). www.fasebj.org
- 25 January 2017
- Published by Taylor & Francis in International Journal of Food Sciences and Nutrition
- Vol. 68 (6) , 712-718
Photoprotection by pistachio bioactives in a 3-dimensional human skin equivalent tissue model
Reactive oxygen species (ROS) generated during ultraviolet (UV) light exposure can induce skin damage and aging. Antioxidants can provide protection against oxidative injury to skin via “quenching” ROS. Using a validated 3-dimensional (3D) human skin equivalent (HSE) tissue model that closely mimics human skin, we examined whether pistachio antioxidants could protect HSE against UVA-induced damage. Lutein and γ-tocopherol are the predominant lipophilic antioxidants in pistachios; treatment with these compounds prior to UVA exposure protected against morphological changes to the epithelial and connective tissue compartments of HSE. Pistachio antioxidants preserved overall skin thickness and organization, as well as fibroblast morphology, in HSE exposed to UVA irradiation. However, this protection was not substantiated by the analysis of the proliferation of keratinocytes and apoptosis of fibroblasts. Additional studies are warranted to elucidate the basis of these discordant results and extend research into the potential role of pistachio bioactives promoting skin health.
- 25 January 2017
- Published by Taylor & Francis in International Journal of Food Sciences and Nutrition
- Vol. 68 (6) , 712-718
Photoprotection by pistachio bioactives in a 3-dimensional human skin equivalent tissue model
Reactive oxygen species (ROS) generated during ultraviolet (UV) light exposure can induce skin damage and aging. Antioxidants can provide protection against oxidative injury to skin via “quenching” ROS. Using a validated 3-dimensional (3D) human skin equivalent (HSE) tissue model that closely mimics human skin, we examined whether pistachio antioxidants could protect HSE against UVA-induced damage. Lutein and γ-tocopherol are the predominant lipophilic antioxidants in pistachios; treatment with these compounds prior to UVA exposure protected against morphological changes to the epithelial and connective tissue compartments of HSE. Pistachio antioxidants preserved overall skin thickness and organization, as well as fibroblast morphology, in HSE exposed to UVA irradiation. However, this protection was not substantiated by the analysis of the proliferation of keratinocytes and apoptosis of fibroblasts. Additional studies are warranted to elucidate the basis of these discordant results and extend research into the potential role of pistachio bioactives promoting skin health.